



Published in final edited form as:

Curr Opin Pediatr. 2008 October ; 20(5): 560–565. doi:10.1097/MOP.0b013e32830fe3d2.

Pediatric Bipolar Disorder: Recognition in Primary Care

Colleen M. Cummings, M.A.¹ and Mary A. Fristad, Ph.D., ABPP^{1,2}

¹ *The Ohio State University, Department of Psychology*

² *The Ohio State University, Department of Psychiatry*

Abstract

Purpose of Review—Bipolar disorder (BPD) is increasingly diagnosed in youth in both outpatient and inpatient settings. Research on BPD in youth has also increased dramatically; this paper summarizes issues of clinical relevance in primary care, advancements in the past year, and areas where more research is needed.

Recent Findings—Key issues and new developments are summarized in the following areas: epidemiology and relevance; assessment and differential diagnosis; patient and family decision support; shared decision making and triage; treatment; and monitoring and collaboration with mental health professionals. Recent practice guidelines have important implications for diagnosis and treatment.

Summary—Early-onset BPD appears to have a more severe course and more comorbidity than later life onset, as well as longer delays in treatment-seeking. Affected children show differences in cognitive functioning and neuroanatomy compared to the general population. Assessment of BPD in children needs to be comprehensive and longitudinal, as diagnosis remains a debated topic. Medications are a primary part of treatment, but more double-blind, placebo controlled trials are needed. Psychosocial adjunctive treatment is important. Children with a family history of BPD are at-risk for impaired functioning and psychopathology; high-risk studies will increase our understanding of the onset and course of BPD.

Keywords

bipolar disorder; children; diagnosis; treatment; recognition

Introduction

Epidemiological studies suggest striking increases in rates of youth diagnosed with BPD in both office-based settings [1*] and hospitals [2]. Research on BPD in youth has also increased dramatically; this paper summarizes: 1) epidemiology and relevance; 2) assessment and differential diagnosis; 3) patient and family decision support; 4) shared decision making and triage; 5) treatment; and 6) monitoring and collaboration with mental health professionals, with special emphasis on advancements of the past year.

Epidemiology and Relevance

The diagnosis of BPD in youth continues to be hotly debated [3,4,5**]. Two recent studies indicate greatly increased rates of diagnosis in outpatients [1*] and inpatients [2]. Several possible reasons for this change in diagnostic practice are offered. For outpatients, delays in

Mary A. Fristad, PhD, ABPP, The Ohio State University, Neuroscience Facility, 1670 Upham Drive, Suite 460G, Columbus, OH 43210-1250, Phone: (614)293-4572, Fax: (614)293-4949, mary.fristad@osumc.edu.

treatment-seeking and less clinical and public awareness of BPD led to underdiagnosis in the past [1*]. For inpatients, increases in diagnoses may reflect frequent rehospitalizations of BPD patients; improved detection with increasing knowledge of BPD; or “upcoding” behavioral problems to BPD to secure reimbursement from insurance companies [2].

Several subtypes of BPD exist, including Bipolar I Disorder (BP-I), Bipolar II Disorder (BP-II), Bipolar Disorder-Not Otherwise Specified (BP-NOS), and Cyclothymic Disorder. BP-I consists of one or more manic episodes (typically in association longitudinally with depression), BP-II consists of depressive and hypomanic episodes, and BP-NOS includes disorders with bipolar features not meeting criteria for BP-I or BP-II. Cyclothymic Disorder consists of hypomanic episodes and depressive symptoms not meeting criteria for a major depressive episode [6]. Definitions for each of these appear below. Work is underway to clarify boundaries between these bipolar spectrum disorders (BPSD). In a sample of 217 children and adolescents with BPSD, patients with BP-I (35.9%) more likely experienced elated mood and psychotic symptoms [7*]. Youth with BP-II (44.7%) were more likely to report depression, were less severely impaired, and had the highest co-occurrence with anxiety disorders. BP-NOS subjects (19.4%) had an earlier onset, irritable mood, an episodic course, and more frequent comorbidity with attention-deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD).

Assessment and Differential Diagnosis

A manic episode is “a distinct period of abnormally and persistently elevated, expansive, or irritable mood, lasting at least 1 week (or any duration if hospitalization is necessary),” accompanied by three or more of the following symptoms: inflated self-esteem, decreased need for sleep, more talkative than usual, flight of ideas or racing thoughts, distractibility, increase in goal-directed activity, and excessive involvement in dangerous activities that have a high potential for dangerous consequences [6, p. 362]. A hypomanic episode is “a distinct period of persistently elevated, expansive, or irritable mood, lasting throughout at least four days,” accompanied by at least three of the symptoms of mania listed above [6, p. 368].

A major depressive episode consists of five or more of the following symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in activities, significant weight loss or gain or a decrease or increase in appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive or inappropriate guilt, diminished ability to concentrate or indecisiveness, and recurrent thoughts of death or suicidality [6].

Chang [8] argues that pediatric BPD (strictly defined BP-I and BP-II) is continuous with adult forms of the disorder. Similar symptoms in children and adults (taking developmental differences into account), childhood-onset reported in adults with BPD, family studies, and biological characteristics provide compelling evidence for this position [8]. However, youth frequently do not meet strictly defined criteria of BP-I and BP-II, presenting instead with severe mood dysregulation and features indicative of BPD.

Recommendations for the assessment of BPD in youth include use of screening questionnaires, DSM-IV-TR criteria, and caution in applying the diagnosis to preschoolers [5**]. BP-II is frequently underdiagnosed in youth who present with major depressive disorder (MDD), to avoid this mistake, a longitudinal, lifetime history must be gathered [9*].

Comorbidity

Further complicating diagnosis is the frequent occurrence of comorbidity. In a sample of 147 Turkish children with ADHD, children with comorbid BPD (8.2%) had higher rates of ODD,

panic disorder, a family history of BPD, and more problems on the Child Behavior Checklist (CBCL) and Young Mania Rating Scale (YMRS) than children with ADHD and no BPD [10]. Conduct problems are also common. Over half of adolescent inpatients with BPD had a least one offense prior to hospitalization, most commonly, larceny-theft, domestic violence, and drug law violations [11*]. Offenders were more likely to be older at first treatment and sexually active in the past month than non-offenders, who were more likely to have used stimulants and to have an anxiety disorder [11*]. Adults who reported conduct problems in childhood were 2.6 to 3.5 times more likely to have BP-II compared to those who did not report such problems, even after controlling for socio-economic status [12].

Sex differences

No sex differences in rates of BPSD or in bipolar subtypes were noted in 387 youth diagnosed with BPSD [13]. Males were more likely to present in a manic state while females were more likely to present in a depressed state. There were no sex differences in mixed mood states [13].

Cognitive function

Children with BPD show impairments in cognitive flexibility, or the ability to adapt to changing circumstances in the environment, compared to healthy controls [14]. They are also less adept than healthy controls in identifying emotionally intense happy and sad faces [15]. Children with BPD and a comorbid anxiety disorder (BPD+ANX) demonstrated a bias toward threatening faces, while children with BPD and no comorbid anxiety disorder (BPD-ANX) and controls demonstrated no such bias [16**], suggesting BPD+ANX and BPD-ANX may have different pathophysiologies and thus require different treatment approaches [16**].

Neuroanatomy

Magnetic resonance imaging (MRI) scans of orbitofrontal cortex (OFC) regions in 14 youth diagnosed with BPD and 20 healthy controls demonstrate significant gender interactions [17*]. Females with BPD had larger gray matter volumes in left, lateral, and left lateral OFC regions compared to female controls, and showed a significant trend for larger volumes in the right lateral and medial left regions of the OFC. Males with BPD had significantly smaller gray matter volumes in the medial, right medial, and right lateral OFC regions compared to male controls [17*].

Family history

Youth with early-onset BPD tend to have higher percentages of first-degree relatives with various mental and emotional disorders than adolescents with later-onset BPD [18*]. Youth with a more classical BPD presentation are more likely to have parents with a BPD diagnosis, compared to youth with severe mood dysregulation but no diagnosed BPSD [19]. Children of parents with BPD have more social impairment [20] and higher parent-rated and child-rated irritability compared to control children, even after adjusting for child psychopathology, suggesting a possible genetic link between BPD and irritability in offspring [21].

Onset

Sleep and anxiety disorders, and ADHD have been identified as antecedent conditions in those who eventually develop BPD [22**]. Stressful life events often trigger episode onset, particularly for those at-risk youth noted to be high in “emotionality,” a particular temperamental profile that suggests sensitivity to stressful life events [23*]. Frequent “ups and downs,” anxious or depressive episodes, disruptive behavior disorders, symptoms potentially indicating mania (e.g., signs of irritability, elated mood, racing thoughts) positive family

history, and lower overall functioning are all common in the prodrome of youth who develop BPSD [24,25].

Screening questionnaires

No simple screen or self-report measure is a substitute for careful clinical interview. Researchers have evaluated various instruments to identify BPD in youth, including the CBCL [26,27,28] and Child Bipolar Questionnaire (CBQ) [29]. The CBCL is unlikely to provide much specific guidance for the diagnosis of BPD, since profiles are variable and do not correlate with BPD diagnosis from semi-structured interviews [28]. The CBQ's dimensional approach may be useful for genetic studies of BPD [29]. Although scales may be helpful for early screening and supplemental information, cross-sectional assessments of a child's symptoms are inadequate for diagnosis.

Differential diagnosis

Not all irritability or "mood swings" result in a diagnosis of BPSD. Irritability and psychomotor agitation are to children's mental health what fever is to children's physical health. They are indicators of a problem, but do not equate to any particular diagnosis; rather, they can reflect developmental, behavioral, anxiety, mood or psychotic disorders—in other words, the gamut of children's emotional and behavioral disorders. Critical to the diagnosis of a BPSD is the temporal clustering of symptoms previously described accompanied by clear impairment in functioning.

Summary

Findings discussed above suggest clinicians must gather a thorough, integrative history that embeds a lifetime history of mood symptoms and episodes in the context of the child's pre- and perinatal history, developmental, family, medical, social, academic, and treatment history. Comorbid disorders are common, and complicate diagnosis. Sex differences do not appear in rates of BPSD, but girls and boys may present in different mood states. Children with BPD may present with differences in cognitive function and neuroanatomy. It is essential to assess family history when considering a BPSD diagnosis.

Five questions the primary care physician should remember are: 1) are there sustained periods of time (e.g., more than an hour or two in a day) when the child becomes too silly or giddy for hours at a time with no explanation (including paradoxical reaction to medications)?; 2) are there sustained periods of time (e.g., more than an hour or two in a day) when the child has *extreme* bouts of irritability, not in keeping with his usual temperament?; 3) during the same period of time when the child's mood becomes too high or too intensely irritable, does the child sleep far less than usual? 4) during this same period of time, does the child seem to be "going too fast"—pressured speech, racing thoughts, or clearly reckless behavior/exhibiting out-of-character poor judgment? 5) is there a family history of BPD (or depression in both sides of the family)?

Patient and Family Decision Support

It is critical that families be taught and empowered to play an active role in their child's treatment. Likewise, children must be educated to understand and manage their symptoms. Primary care physicians can utilize the treatment guidelines summarized below to provide care, information and support to youth with BPD and their families.

Longitudinal course

It is critical for patients and families to understand that BPSD appear to be lifelong conditions with symptoms that wax and wane over time. Age of onset is relatively evenly divided across

childhood (14%), adolescence (36%), early adulthood (32%), and late adulthood (19%) [30]. Paradoxically, individuals with childhood-onset BPD had longer delays from disorder onset to treatment (approximately 16 years) than those with onset later in life. Childhood and adolescent onset is related to more episodes, comorbid disorders, rapid cycling, and more severe mania and depression [30]. Childhood-onset BPD more commonly includes irritability, conduct problems, and higher rates of comorbidity; adolescent-onset BPD has higher rates of psychotic symptoms [31]. Individuals with early-onset are more likely to be female, experience more psychotic symptoms, and have greater comorbidity, a more severe illness, and a longer time to first treatment [32]. It is worth noting that some youth who present with a major depressive disorder will go on to develop a course later in life consistent with BPD. The risk of a depressed youth eventually developing BPD may be increased in those suffering from psychotic depression, who experience rapid onset or offset of their depression, and who develop symptoms of mania or hypomania when treated with antidepressant medication.

Treatment adherence

Treatment adherence is often low in this population [33**], complicating clinical outcome. A proactive discussion with patient and family of the risks of nonadherence in a chronic disorder such as BPD is advisable. Twelve months post-hospitalization for 71 adolescents with BPD, only 35% of the adolescents reported full medication adherence. Comorbid ADHD, anxiety, and disruptive behavior disorders, nonadherence to medications, and lower socioeconomic status were predictors of poor recovery [33**].

Shared Decision Making and Triage

Parents are often reluctant to have their child try medications recommended for BPSD—mood stabilizers and/or atypical antipsychotic medication, as these drugs carry with them significant risk for adverse events. It is critical that parents and children be appraised of means to monitor their: 1) moods and treatment response via mood charting; 2) side effects so they can, in conjunction with their physician, determine whether the total dose, distribution of dose, or type of medicine require modification. If possible, referral to a child and adolescent psychiatrist is recommended, although this is not realistic or adequately timely in all communities. Thus, medication recommendations appear below which primary care physicians can use to initiate treatment.

Treatment

Medications and adjunctive psychoeducational psychotherapy have demonstrated efficacy in treating BPD.

Medications

Medications are an essential first step in treating children with BPD [5**,34,35]. Guidelines are available for treating children with BP-I [5**]. Ideally, children should begin treatment with medication approved by the Food and Drug Administration (FDA) for BPD. Only lithium was FDA approved for children when existing treatment guidelines were published; subsequently, risperidone and aripiprazole have also been approved for BPD youth. Most children will require ongoing medication therapy to manage their disorder and to prevent relapse, drawing a balance between maximizing symptom relief and minimizing untoward side effects [5**]. Medications should be monitored for a sufficient length of time (e.g., six to eight weeks for mood stabilizers) to determine effectiveness. Judicious use of polypharmacy, both to treat the BPD as well as comorbid conditions, is often necessary [5**], yet poorly studied. A decision-making strategy regarding when to augment, switch, or continue a medication for a child with BPD is available [36] that is based on expert consensus. There is a dire need for

more double-blind, placebo controlled trials, and studies of treating the depressed phase of BPD, comorbidities, and relapse-prevention [35,37].

Three open-label prospective studies found aripiprazole [38], ziprasidone [39] and omega-3 fatty acids [40] to be associated with clinically significant improvement in BPD youth. Adolescents with BP-I experienced improved health-related quality of life following trials with either divalproex or quetiapine [41]. A single-blind trial found quetiapine to be effective in adolescents at high-risk for developing BP-I [42]. High-risk was defined as youth diagnosed with BP-NOS, dysthymia, BP-II, cyclothymia, or MDD, all of whom had a first degree relative with BPD [42]. However, another high-risk treatment study that employed a double-blind, placebo controlled methodology found that treatment with divalproex sodium for up to five years did not lead to significant symptom improvement compared to placebo for offspring of parents with BPD and who had diagnoses of BPD-NOS or cyclothymia [43**].

Psychotherapy

Adjunctive psychoeducational psychotherapy teaches families about the symptoms of BPD as well as its biopsychosocial management, which includes improving family problem solving and communication skills in order to better manage symptoms. Psychoeducational psychotherapy has demonstrated efficacy in treating BPSD, both acutely [44] and as maintenance treatment [45**]. Additionally, family-based psychoeducational psychotherapy results in reduced variance in the number of medications taken from pre- to post-treatment, suggesting this treatment helps parents become better consumers of mental health care, in particular, medication management [46]. Physicians should recommend therapy for families of children with BPD, to help inform and empower families and maintain treatment gains. Collaboration between the family, prescribing physician and therapist is an important part of care.

Monitoring and Collaboration

Treatment for children with BPD requires ongoing monitoring and collaboration.

Monitoring

Baseline and periodic laboratory assessments are needed to ensure safety when prescribing medications to children with BPD. These are described below.

Before prescribing lithium, obtain complete blood cell counts, thyroid function tests, urinalysis, blood urea nitrogen, creatinine, serum calcium levels, and a pregnancy test, if appropriate. Once the patient is stabilized on an appropriate dosage of lithium, lithium levels, renal and thyroid function and urinalysis should be monitored on an ongoing basis [5**].

Prior to prescribing valproate, obtain liver function tests, complete blood cell counts, and a pregnancy test, if appropriate. Continuous monitoring of serum drug levels, hepatic and hematological indices are in order once the patient is stabilized [5**].

Before prescribing atypical antipsychotics, obtain a baseline body mass index, waist circumference, blood pressure, fasting glucose levels, and a fasting lipid panel. Monitor body mass index, blood pressure, fasting glucose levels, and lipids continuously during treatment. Specific antipsychotic agents may have varying requirements [5**].

We know little about long-term effects of medications often prescribed for children with BPD. Additionally, short-term side effects (e.g., weight gain and cognitive side effects) must be carefully monitored. Once a patient is stabilized on an appropriate dosage of a medication, maintenance treatment should continue with the goal of relapse prevention. Ongoing

monitoring for symptom recurrence, including suicide risk and to improve functioning at home, school, and with peers is important.

Collaboration

In general, referral to a specialist is recommended; however, even when a referral is readily available, collaborative care with the specialist may be required to monitor potential adverse events. Referral to a mental health professional may not always be feasible or acceptable to the patient and family.

Conclusion

In summary, knowledge of BPD in children is rapidly increasing. Assessments must be longitudinal and comprehensive. As BPD often manifests early and is most likely a lifetime condition, patient and family support is crucial to give families the skills to manage the disorder. While medications are an essential treatment component, more randomized, placebo-controlled trials are needed, especially for combination treatments. Adjunctive psychosocial treatments are crucial. When prescribing medications, baseline laboratory assessments and careful periodic monitoring of side effects is necessary. Referral and/or collaboration with a mental health specialist is strongly recommended.

References

- *1. Moreno C, Laje G, Blanco C, et al. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. *Arch Gen Psychiatry* 2007;64(9):1032–1039. [PubMed: 17768268]This paper documents and considers the striking increases in rates of youth diagnosed with BPD in office-based settings
2. Blader JC, Carlson GA. Increased rates of bipolar disorder diagnoses among U.S. child, adolescents, and adult inpatients, 1996–2004. *Biol Psychiatry* 2007;62:107–114. [PubMed: 17306773]
3. Cahill C, Hanstock T, Jairam R, et al. Comparison of diagnostic guidelines for juvenile bipolar disorder. *Australian and New Zealand Journal of Psychiatry* 2007;41(6):479–484. [PubMed: 17508317]
4. Duffy A. Does bipolar disorder exist in children? A selected review *Can J Psychiatry* 2007;52(7):409–417.
- **5. McClellan J, Kowatch R, Findling RL, et al. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. *J Am Acad Child Adolesc Psychiatry* 2007;46(1):107–125. [PubMed: 17195735]The authors present evidence-based practice parameters for assessment and treatment of children and adolescents with BPD in response to a dire need for practitioner guidelines
6. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. Vol. 4. Washington, DC: American Psychiatric Association; 2000.
- *7. Masi G, Perugi G, Millepiedi S, et al. Clinical implications of DSM-IV subtyping of bipolar disorders in referred children and adolescents. *J Am Acad Adolesc Psychiatry* 2007;46(10):1299–1306.This paper identifies differences in youth with BP-I, BP-II cyclothymic disorder, and BP-NOS, helping to clarify boundaries between the various bipolar spectrum disorders
8. Chang K. Adult bipolar disorder is continuous with pediatric bipolar disorder. *Can J Psychiatry* 2007;52:418–425. [PubMed: 17688005]
- *9. Raman RPB, Sheshadri SP, Reddy YCJ, et al. Is bipolar II disorder misdiagnosed as major depression disorder in children? *Journal of Affective Disorders* 2007;98:263–266. [PubMed: 16949161]The authors note the relatively common underdiagnosis of BP-II in youth who present with MDD, emphasizing the importance of gathering an extensive longitudinal history when making a diagnosis
10. Diler RS, Uguz S, Seydaoglu G, et al. Differentiating bipolar disorder in Turkish prepubertal children with attention-deficit hyperactivity disorder. *Bipolar Disord* 2007;9:243–251. [PubMed: 17430299]
- *11. Barzman DH, DelBello MP, Fleck DE, et al. Rates, types and psychosocial correlates of legal charges in adolescents with newly diagnosed bipolar disorder. *Bipolar Disord* 2007;9:339–344. [PubMed:

17547580]The authors identify rates and predictors of conduct problems in youth before their first hospitalization for BPD. Conduct problems commonly co-occur in children with BPD, and warrant further study

12. Endrass J, Vetter S, Gamma A, et al. Are behavioral problems in childhood and adolescents associated with bipolar disorder in early adulthood? *Eur Arch Psychiatry Clin Neurosci* 2007;257:217–221. [PubMed: 17287927]
13. Duax JM, Youngstrom EA, Calabrese JR, Findling RL. Sex differences in pediatric bipolar disorder. *J Clin Psychiatry* 2007;68(10):1565–1573. [PubMed: 17960974]
14. Dickstein DP, Nelson EE, McClure EB, et al. Cognitive flexibility in phenotypes of pediatric bipolar disorder. *J Am Acad Child Adolesc Psychiatry* 2007;46(3):341–355. [PubMed: 17314720]
15. Schenkel LS, Pavuluri MN, Herbener ES, et al. Facial emotion processing in acutely ill and euthymic patients with pediatric bipolar disorder. *J Am Acad Child Adolesc Psychiatry* 2007;46(8):1070–1078. [PubMed: 17667485]
- **16. Brotman MA, Rich BA, Schmajuk M, et al. Attention bias to threat faces in children with bipolar disorder and comorbid lifetime anxiety disorders. *Biol Psychiatry* 2007;61:819–821. [PubMed: 17338904]This paper examines the influence of comorbidity on cognitive processes in children with BPD, suggesting different pathophysiology in children with BPD and comorbid anxiety, and BPD but no comorbid anxiety
- *17. Najt P, Nicoletti M, Chen HH, et al. Anatomical measurements of the orbitofrontal cortex in child and adolescents patients with bipolar disorder. *Neuroscience Letters* 2007;413:183–186. [PubMed: 17276600]This paper examines abnormalities in the orbitofrontal cortex in children with BPD. More research on the neuroanatomy of children with BPD is necessary to learn more about the physiological factors of BPD
- *18. Rende R, Birmaher B, Axelson D, et al. Childhood-onset bipolar disorder: evidence for increased familial loading of psychiatric illness. *J Am Acad Child Adolesc Psychiatry* 2007;46(2):197–204.This study compares heritability in childhood-onset BPD to adolescent-onset BPD, an important factor in gaining better understanding of the differences between the two
19. Brotman MA, Kassem L, Reising MM, et al. Parental diagnoses in youth with narrow phenotype bipolar disorder or severe mood dysregulation. *Am J Psychiatry* 2007;164:1238–1241. [PubMed: 17671287]
20. Reichart CG, van der Ende J, Wals M, et al. Social functioning of bipolar offspring. *Journal of Affective Disorders* 2007;98:207–213. [PubMed: 16920198]
21. Farchione TR, Birmaher B, Axelson D, et al. Aggression, hostility, and irritability in children at risk for bipolar disorder. *Bipolar Disord* 2007;9:496–503. [PubMed: 17680920]
- **22. Duffy A, Alda M, Crawford L, et al. The early manifestations of bipolar disorder: a longitudinal prospective study of the offspring of bipolar parents. *Bipolar Disord* 2007;9:828–838. [PubMed: 18076532]This is an important longitudinal study that assessed children at-risk for BPD, suggesting non-specific psychopathology and depression may often precede BPD, advocating for careful assessment of at-risk children
- *23. Duffy A, Alda M, Trinneer A, et al. Temperament, life events, and psychopathology among the offspring of bipolar parents. *Eur Child Adolesc Psychiatry* 2007;16:222–228. [PubMed: 17136299] This study found psychopathology was associated with recent negative life events, and this association was mediated by emotionality in offspring at risk for BPD. This has important treatment and preventative implications for at-risk children
24. Singh MK, DelBello MP, Stanford KE, et al. Psychopathology in children of bipolar parents. *Journal of Affective Disorders* 2007;102:131–136. [PubMed: 17275096]
25. Hauser M, Pfennig A, Ozgurda S, et al. Early recognition of bipolar disorder. *European Psychiatry* 2007;22:92–98. [PubMed: 17142013]
26. Giles LL, DelBello MP, Stanford KE, Strakowski SM. Child behavior checklist profiles of children and adolescents with and at high risk for developing bipolar disorder. *Child Psychiatry Hum Dev* 2007;38:47–55. [PubMed: 17160586]
27. Holtman M, Bolte S, Goth K, et al. Prevalence of the Child Behavior Checklist- pediatric bipolar disorder phenotype in a German general population sample. *Bipolar Disord* 2007;9:895–900. [PubMed: 18076540]

28. Volk HE, Todd RD. Does the Child Behavior Checklist juvenile bipolar disorder phenotype identify bipolar disorder? *Biol Psychiatry* 2007;62:115–120. [PubMed: 16950211]
29. Papolos D, Hennen J, Cockerham MS, Lachman H. A strategy for identifying phenotypic subtypes: concordance of symptom dimensions between sibling pairs who met screening criteria for a genetic linkage study of childhood-onset bipolar disorder using the Child Bipolar Questionnaire. *Journal of Affective Disorders* 2007;99:27–36. [PubMed: 17049378]
30. Leverich GS, Post RM, Keck PE, et al. The poor prognosis of childhood-onset bipolar disorder. *J Pediatr* 2007;150:485–490. [PubMed: 17452221]
31. Lazaro L, Castro-Fornieles J, Eugenio de la Fuente J, et al. Differences between prepubertal-versus adolescent-onset bipolar disorder in a Spanish clinical sample. *Eur Child Adolesc Psychiatry* 2007;16:510–516. [PubMed: 17846818]
32. Souminen K, Mantere O, Valtonen H, et al. Early age at onset of bipolar disorder is associated with more severe clinical features but delayed treatment seeking. *Bipolar Disord* 2007;9:698–705. [PubMed: 17988359]
- **33. DelBello MP, Hanseman D, Adler CA, et al. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. *Am J Psychiatry* 2007;164:582–590. [PubMed: 17403971] This study examines 12-month outcome of adolescents who had been hospitalized for BPD, and identifies factors that are predictive of poor recovery
34. Harmin V, Pachler M. Pediatric bipolar disorder: evidence-based psychopharmacological treatments. *Journal of Child and Adolescent Psychiatric Nursing* 2007;20(1):40–58. [PubMed: 17284237]
35. Smarty S, Findling RL. Psychopharmacology of pediatric bipolar disorder: a review. *Psychopharmacology* 2007;191:39–54. [PubMed: 17093980]
36. Dawson R, Lavori PW, Luby JL, et al. Adaptive strategies for treating childhood mania. *Biol Psychiatry* 2007;61:758–764. [PubMed: 17166485]
37. Consoli A, Deniau E, Huynh C, et al. Treatments in child and adolescent bipolar disorders. *Eur Child Adolesc Psychiatry* 2007;16:187–198.
38. Biederman J, Mick E, Spenser T, et al. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. *CNS Spectr* 2007;12(9):683–689. [PubMed: 17805214]
39. Biederman J, Mick E, Spencer T, et al. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. *Bipolar Disord* 2007;9:888–894. [PubMed: 18076539]
40. Wozniak J, Biederman J, Mick E, et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. *European Neuropsychopharmacology* 2007;17:440–445. [PubMed: 17258897]
41. Rademacher J, Delbello MP, Adler C, et al. Health-related quality of life in adolescents with bipolar I disorder. *Journal of Child and Adolescent Psychopharmacology* 2007;17(1):97–103. [PubMed: 17343557]
42. DelBello MP, Adler CM, Whitsel RM, et al. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. *J Clin Psychiatry* 2007;68(5):789–795. [PubMed: 17503991]
- **43. Findling RL, Frazier TW, Youngstrom EA, et al. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. *J Clin Psychiatry* 2007;68(5):781–788. [PubMed: 17503990] This is a five-year, double-blind study of divalproex monotherapy in symptomatic, at-risk children. It reflects the need for more double-blind, placebo-controlled medication trials as well as interventions for youth at risk for BDP
44. Young ME, Fristad MA. Evidence based treatments for bipolar disorder in children and adolescents. *Journal of Contemporary Psychotherapy* 2007;37:157–164.
- **45. West AE, Henry BD, Pavuluri MN. Maintenance model of integrated psychosocial treatment in pediatric bipolar disorder: a pilot feasibility study. *J Am Acad Child Adolesc Psychiatry* 2007;46(2):205–212. [PubMed: 17242624] This is the first study to examine three year maintenance of treatment gains for a long-term psychosocial treatment for children with BPD

46. Cummings CM, Fristad MA. Medications prescribed to children with mood disorders: effects of a family-based psychoeducation program. *Experimental and Clinical Psychopharmacology* 2007;15(6):555–562. [PubMed: 18179308]